Vernalis selects Corvus Pharmaceuticals as global licensee for adenosine antagonist program
In February 2015, the company licensed exclusive, worldwide rights in its adenosine receptor antagonist programme for use in all therapeutic applications to Corvus, a U.S.-based biotechnology company. At
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.